Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Gynecologic Cancer

 

Carboplatin + Paclitaxel w/wo Bevacizumab After Surgery (GOG 213)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreduction Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer

Investigator: Benjamin E. Greer, MD;   Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer;    Status: Recruiting;   Study ID: NCT00565851

FDG PET for Advanced Ovarian Cancer (FHCRC-7009)
FDG PET and Biomarkers in Treatment Response in Advanced Ovarian Cancer

Investigator: Dr. Joseph Rajendran;   Conditions: Advanced Ovarian Cancer;    Status: Recruiting

Elesclomol Sodium and Paclitaxel for Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (GOG 0260)
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Investigator: Heidi Gray, MD;   Conditions: Fallopian Cancer, Ovarian Cancer, Primary Peritoneal Cancer (PPC);    Status: Recruiting;   Study ID: NCT00888615

Paclitaxel With or Without Pazopanib in Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (GOG 186-J)
A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) (IND #75648) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

Investigator: Benjamin Greer, MD;   Conditions: Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cavity Cancer;    Status: Recruiting;   Study ID: NCT01468909

BIBF 1120 in Recurrent or Persistent Endometrial Cancer (GOG 229-K)
A Phase II Evaluation of BIBF 1120 (IND #) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Investigator: Benjamin Greer, MD;   Conditions: Endometrial Cancer;    Status: Recruiting;   Study ID: NCT01225887

Memory and Thinking Skills Workshop in Improving Cognitive Rehabilitation in Ovarian Cancer Survivors (7750)
Behavioral and Neural Indices of Cognitive Rehabilitation in Ovarian Cancer: A Pilot Study

Investigator: Heidi J. Gray, MD;   Conditions: Ovarian Cancer;    Status: Recruiting;   Study ID: NCT01641068

Novel Markers to Predict Malignancy in Elevated-Risk Women (Novel Markers Trial--6973)
A Randomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women (Novel Markers Trial)

Investigator: Nicole Urban, Sc.D., ScD;   Conditions: Ovarian Cancer;    Status: Recruiting;   Study ID: NCT01121640

Rucaparib for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (CO-338-017)
A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Investigator: Elizabeth Swisher, MD;   Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer;    Status: Recruiting;   Study ID: NCT01891344

Cabozantinib or Paclitaxel Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (GOG -186K)
A Randomized Phase Ii Study Of Nci Supplied Cabozantinib (Nsc #761968 Ind #116059) Versus Weekly Paclitaxel (Nsc #673089) In The Treatment Of Persistent Or Recurrent Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Cancer

Investigator: Benjamin Greer, MD;   Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer;    Status: Recruiting;   Study ID: NCT01716715

Radiation Therapy Stage I or Stage II Cervical Cancer Post Surgery (GOG 0263)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy

Investigator: ;   Conditions: Cervical Cancer;    Status: Recruiting;   Study ID: NCT01101451

VTX-2337 + Pegylated Liposomal Doxorubicin (PLD) Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (GOG-3003)
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Investigator: Heidi J Gray, MD ;   Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer;    Status: Recruiting;   Study ID: NCT01666444

MRI- and PET-Predictive-Assay for Cervical Cancer (8118)
MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix

Investigator: Nina Mayr, MD;   Conditions: Cervical Cancer;    Status: Recruiting;   Study ID: NCT01992861

ID-LV305 for Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Investigator: Seth M. Pollack, MD;   Conditions: Breast Cancer, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer, Sarcoma;    Status: Recruiting;   Study ID: NCT02122861

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT01988896